firtecan pegol (PEG-SN38) / Belrose, Zhejiang Hisun  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
firtecan pegol (PEG-SN38) / Belrose
NCT00520637: A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)

Completed
1
34
US
EZN-2208
Enzon Pharmaceuticals, Inc.
Advanced Solid Tumors, Lymphoma
 
 
NCT00520390: A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)

Checkmark
Apr 2013 - Apr 2013: 
Completed
1
34
US
EZN-2208
Enzon Pharmaceuticals, Inc.
Lymphoma, Advanced Solid Tumors
 
 
NCT01251926: EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors

Checkmark In combination with bevacizumab in pts with refractory solid tumors
Nov 2013 - Nov 2013: In combination with bevacizumab in pts with refractory solid tumors
Checkmark AACR-2013
Mar 2013 - Mar 2013: AACR-2013
Completed
1
12
US
EZN-2208, Bevacizumab
National Cancer Institute (NCI)
Neoplasms
 
04/14

Download Options